Chemical Fingerprinting and Biological Evaluation of the Endemic Chilean Fruit *Greigia sphacelata* (Ruiz and Pav.) Regel (Bromeliaceae) by UHPLC-PDA-Orbitrap-Mass Spectrometry

Ruth E. Barrientos ^{1,+}, Shakeel Ahmed ^{1,+}, Carmen Cortés ¹, Carlos Fernández-Galleguillos ¹, Javier Romero-Parra ², Mario J. Simirgiotis ^{1,*} and Javier Echeverría ^{3,*}

- ¹ Instituto de Farmacia, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5090000, Chile; ruth.barrientos@alumnos.uach.cl (R.E.B.), shakeel.ahmed@uach.cl (S.A.), carmenc1012@gmail.com (C.C.), carlos.fernandez@uach.cl (C.F.-G.)
- ² Departamento de Química Orgánica y Fisicoquímica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Olivos 1007, Casilla 233, Santiago, Chile, javier.romero@ciq.uchile.cl
- ³ Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Casilla 40, Correo 33, Santiago 9170002, Chile
- * Correspondence: mario.simirgiotis@gmail.com or mario.simirgiotis@uach.cl (M.J.S.); javier.echeverriam@usach.cl (J.E.); Tel.: +56-63-63233257 (M.J.S.); +56-2-27181154 (J.E.)
- ⁺ These authors contributed equally to this study

Received: 03 July 2020; Accepted: 14 August 2020; Published: August 2020

Keywords: *Greigia sphacelata*, endemic fruits, UHPLC-PDA-Orbitrap-MS, metabolomic analysis, antioxidant, cholinesterase inhibition



Figure S1 (a-v): Full MS spectra and structures of compounds **1**, **3**, **7**, **9**, **12**, **13**, **15**, **25**, **27**, **28**, **29**, **35**, **37**, **42**, **43**, **44**, **46**, **48**, **51**, **53** and **55**.





















Docking analyses of Greigia sphacelata main compounds

Material and Methods

Docking simulations were carried for those compounds (Figure S1) that turned out to be the most abundant species according to the UHPLC Chromatogram (Figure 2) obtained from the pulp and seeds of the G. sphacelata's fruit. The geometries and partial charges of quercetin-3-O-glucoside acetate (peak 28), lupinisoflavone A (peak 32), genistein-7-O-di-glucoside (peak 35), ononin (formononetin 7-O-glucoside) (peak 46), genistein-7-O-glucoside (peak 38), aesculetin-O-glucuronide (peak 25), dihydroxy-octadecaenoic acid (peak 62), and hydroxy-pentadecanoic acid (peak 69) were fully optimised using the DFT method with the standard basis set PBE0/ 6-311+g*[1, 2]. All calculations were performed in Gaussian 09W software[3]. Crystallographic enzyme structures of Torpedo californica acetylcholinesterase (TcAChE; PDBID: 1DX6 code[4]) and human butyrylcholinesterase (hBuChE; PDBID: 4BDS code[5]) were downloaded from the Protein Data Bank RCSB PDB[6]. Water molecules and ligands of the crystallographic protein active sites were removed. All polar hydrogen atoms of both enzymes were added and proteins were treated as rigid bodies. Grid maps were calculated using the Autogrid option and were centred on the putative catalytic site of each enzyme considering their known catalytic residues: Ser200, Glu327 and His440 for TcAChE [7, 8] and Ser198, Glu325 and His438 for hBuChE [9, 10] respectively. Ser200 of TcAChE and Ser198 of *h*BuChE were designated as the centre of the grids for the catalytic site of each enzymes. The volumes chosen for the grid maps for both catalytic sites were made up of 60 × 60 × 60 points in the x, y, z directions of 6.634, 63.588, 60,192 for TcAChE and 138.839, 120.098 and 41.943 for hBuChE, respectively. A grid-point spacing of 0.375 Å was established. Docked compound complexes were built using the Lamarckian Genetic Algorithm[11] which involved 100 runs. The lowest dockedenergy binding cluster positions were chosen to be analyzed according to the potential intermolecular interactions between compounds and the enzymes, as well as to obtain the binding mode and docking descriptors. The different complexes were visualised in a Visual Molecular Dynamics program (VMD) and Pymol [12].



Figure S2. Components of G. sphacelata fruits used in docking studies.

Results and Discussion

All Compounds that turned out to be the most abundant species according to the UHPLC Chromatogram (**Figure 2**) obtained from the pulp and seeds of *G. sphacelata*, as well as the known cholinesterase inhibitor galantamine, were subjected to docking assays into the *Tc*AChE catalytic site and *h*BuChE catalytic site, in order to rationalize their pharmacological results analyzing their protein molecular interactions in the light of their experimental inhibition activities showed in **Table 2**. The best docking binding energies expressed in kcal/mol of each compound are shown in **Table S1**.

Table S1. Binding energies obtained from docking experiments of most abundant compounds in *G. sphacelata*'s fruit and the known cholinesterase inhibitor galantamine over acetylcholinesterase (*Tc*AChE) and butyrylcholinesterase (*h*BuChE).

Compound	Binding energy	Binding energy
	(kcal/mol)	(kcal/mol)
	Acetylcholinesterase	Butyrylcholinesterase
	(TcAChE)	(hBuChE)
Quercetin-3-O-glucoside-acetate	-9.46	-8.31
Lupinisoflavone	-9.36	-7.99
Genistein-7-O-di-glucoside	-9.18	-6.89
Ononin (formononetin 7-O-	-7.45	-6.44
glucoside)		
Genistein-7-O-glucoside	-7.24	-5.86
Aesculetin-7-O-glucuronide	-6.67	-6.85
Dihydroxy-octadecaenoic acid	-4.71	-5.76
Hydroxy-pentadecanoic acid	-4.81	-4.87
Galantamine	-11.81	-9.5

Acetylcholinesterase (TcAChE) docking results

Table S1 showed that the flavonoid quercetin-3-O-glucoside-acetate, and the isoflavones Lupinisoflavone and Genistein-7-O-di-glucoside displayed the best binding energies of -9.46, -9.36 and -9.18 kcal/mol, respectively. These results suggest that *G. sphacelata* pulp or seed extracts inhibitory activity over acetylcholinesterase are mainly due the compounds mentioned above, especially the flavonoid quercetin-3-O-glucoside-acetate.

Quercetin-3-*O*-glucoside-acetate perform five different hydrogen bond interactions; two of them are carried out between the hydrogen atoms of the hydroxyl groups (-OH) at position 3'- and 4'- of the phenyl ring of the 4*H*-chromen-4-one framework and the amino acid Glu199. The 4'- hydroxyl group (-OH) also shows a hydrogen bond interaction with Tyr130 through its oxygen atom (**Figure S3**). Moreover, since the 4*H*-chromen-4-one moiety of quercetin-3-*O*-glucoside-acetate possesses two more hydroxyl groups at positions 5- and 7-, each one of them are in charge to perform another hydrogen bond interaction stabilizing the protein–inhibitor complex. The good binding energy value shown by quercetin-3-*O*-glucoside-acetate may be supported by these hydrogen bond interactions profile mentioned above.

Lupinisoflavone exhibit a binding energy value of -9.36 kcal/mol and shows two hydrogen bond interactions through the hydroxyl group (-OH) of phenyl the moiety at position 6- of the 2,3-dihydro-5*H*-furo-chromen-5-one and the amino acids Glu199 and Tyr130. Isoflavone also perform two extra π - π interactions among the residues of Phe288 and Phe 331 with the aromatic rings of benzene in the dihydro-5*H*-furo-chromen-5-one core and the phenyl moiety at posotion 6-. Especially, the first π - π mentioned interaction is probably favoured because of its quite flat chemical structure due its three fused rings.

Even though quercetin-3-O-glucoside-acetate and Lupinisoflavone structures are arranged in different manners into the *Tc*AChE catalytic site, these derivatives were the only compounds of all those shown **Table 2** that presented these hydrogen bond interactions with the same Glu199 and

Tyr130 amino acids at the same time, suggesting that these two residues could play a key role in the *Tc*AChE inhibition when an inhibitor interacts with them.

Genistein-7-*O*-di-glucoside has a binding energy value of -9.18 kcal/mol and shows four hydrogen bond interactions with Asp72, Glu199, Ser200 and Ser286, as well as a π - π interaction between the benzene ring of the 4*H*-chromen-4-one scaffold and Tyr334 (**Figure S3**). Thus, this derivative into the extract represent a good candidate to behave as a *Tc*AChE inhibitor compared to ononin (formononetin 7-*O*-glucoside), genistein-7-*O*-glucoside, aesculetin-7-*O*-glucuronide, dihydroxy-octadecaenoic acid and hydroxy-pentadecanoic acid.

Ononin (formononetin 7-*O*-glucoside) and Genistein-7-O-glucoside possesses resembling chemical structures; hence are settled in similar modes into the *Tc*AChE catalytic site. The latter could be the reason why these derivatives share some interactions with the same amino acids, such as Tyr130 and Phe288, as well as similar binding energy values (-7.45 and -7.24 kcal/mol respectively, see **Table 3**).

The coumarin aesculetin-7-O-glucuronide exhibit only two hydrogen bond interactions with Glu199 through the two hydroxyl groups (-OH) of the glucoronide moiety at positions 3'- and 5' and a binding energy of -6.67 kcal/mol. Therefore, this derivative, as well as the dihydroxy-octadecaenoic acid and the hydroxy-pentadecanoic acid which carry out only few interactions with the catalytic site of the enzyme, presents low binding energies and have no possibilities to perform other sorts of interactions like π - π or T-shaped. Thus, these compounds would not contribute to the enzyme inhibition in a significant manner, even if they are in high proportion into the extracts (**Figure S3**).



Figure S3. Predicted binding mode and predicted intermolecular interactions of all most abundant compounds in *G. sphacelata* pulp and seeds extracts and the residues of *Torpedo californica* acetylcholinesterase (*Tc*AChE) catalytic site. Yellow dotted lines indicate hydrogen bond interactions, cyan dotted lines represent π - π interactions. **A.** Quercetin-3-*O*-glucoside-acetate (flavonoid) into the catalytic site; **B.** Lupinisoflavone (isoflavone) into the catalytic site; **C.** Genistein-7-*O*-di-glucoside (isoflavone) into the catalytic site; **D.** Ononin (formononetin 7-*O*-glucoside) (isoflavone) into the catalytic site; **E.** Genistein-7-*O*-glucoside (isoflavone) into the catalytic site **F.** Aesculetin-7-*O*-glucuronide (coumarin) into the catalytic site **G.** Dihydroxy-octadecaenoic acid (fatty acid) into the catalytic site; **H.** Hydroxy-pentadecanoic acid (fatty acid) into the catalytic site.

Pulp and seeds extract presented considerably abilities to exert an inhibitory potency over the *Tc*AChE enzyme (IC₅₀= 4.94 ± 0.075 for pulp extract and IC₅₀= 4.98 ± 0.042 for seeds extract) considering the known cholinesterase inhibitor galantamine (see table 3). In this sense, **Figure S3** shows the hydrogen bond interactions in a two dimensional diagram of each main and most abundant compounds determined from both extracts into the *Tc*AChE catalytic site in order to summarize the information.

Butyrylcholinesterase (hBuChE) docking results

All binding energies obtained from docking assays over butyrylcholinesterase (*h*BuChE) of the most abundant compounds in the pulp and the seeds extracts showed to be poorer compared to those in *Tc*AChE. These results are consistent with the less inhibitory activity of the extracts over this enzyme shown in table 2 (IC₅₀= 73.86 ± 0.086 for pulp extract and IC₅₀= 78.57 ± 0.064 for seeds extract).

Just like in *Tc*AChE, the flavonoid quercetin-3-*O*-glucoside-acetate exhibited the best binding energy profile, suggesting that this derivative could be the main responsible for the inhibitory activity over the *h*BuChE.

Quercetin-3-*O*-glucoside-acetate binding descriptors over *h*BuChE had certain differences compared to those shown by *Tc*AChE. Quercetin-3-*O*-glucoside-acetate into the *h*BuChE catalytic site perform only three hydrogen bond interactions. Two of them are carried out between the hydroxyl group (-OH) at position 4' in the phenyl moiety of the 4*H*-chromen-4-one framework and the amino acids Glu197 and Tyr128. Moreover, this flavonoid performs a π - π interaction between the catechol ring and the residue of Trp231, and two T-shaped interactions between the catechol ring and the benzene scaffold of the 4*H*-chromen-4-one core as well (**Figure S4**). Nevertheless, the lack of hydrogen bond interactions compared to those carried out by quercetin-3-*O*-glucoside-acetate into the *Tc*AChE catalytic site could explain the less binding energy of the *h*BuChE–quercetin-3-*O*-glucoside-acetate complex.

Lupinisoflavone's *h*BuChE binding energy, as well as that obtained for *Tc*AChE docking assays, presented the second-best profile, hence it could contribute to the inhibitory activity of the extracts over the enzyme. Nonetheless, also this derivative presented less binding energy relating to the obtained over *Tc*AChE docking results, as was aforementioned. Lupinisoflavone perform a hydrogen bond interaction between the oxygen atom of the dihydrofuran ring at position 1- and the residue of His438. Also present a second hydrogen bond interaction through the oxygen atom of the carbonyl of Trp82 and the hydroxyl group (-OH) at position 2' of the phenyl moiety. Both distant interactions can be done owing its flat chemical structure.

Isoflavonoids genistein-7-O-di-glucoside, ononin (formononetin 7-O-glucoside) and genistein-7-O-glucoside due their similar chemical structures are overlapped among them into the *h*BuChE catalytic site, and therefore exhibit related binding modes and similar binding energies as can be seen in table 3. The three isoflavonoids mentioned above perform the same hydrogen bond interaction with His438 through one of the hydroxyl groups (-OH) their glycoside moieties. Likewise, genistein-7-O-di-glucoside and ononin (formononetin 7-O-glucoside) carry out another hydrogen bond interaction through the 3''-OH of their glycosides scaffolds with Trp82, but genistein-7-O-glucoside perform the same interaction through its 3''-OH with the nearby amino acid Trp430. Genistein-7-Odi-glucoside expose a substantial difference compared to the other two isoflavonoids, carrying out an extra hydrogen bond interaction between the 4' phenolic hydroxyl (-OH) and Asn68, what the other derivatives do not perform. This latter feature could explain the best binding energy exhibited by genistein-7-*O*-di-glucoside (-6.89 kcal/mol).

The coumarin aesculetin-7-*O*-glucuronide, as well as the fatty acids dihydroxy-octadecaenoic acid and hydroxy-pentadecanoic acid, like in *Tc*AChE docking assays, showed the worse binding energies, and therefore they are probably not significant contributors for the *h*BuChE inhibition. Aesculetin-7-*O*-glucuronide shows two hydrogen bond interactions with Glu197 through two hydroxyl groups (-OH) of its glycoside core, and the fatty acids also carry out poor interactions being only two hydrogen bond interactions in charge of stabilizing the protein–compound complex in the dihydroxy-octadecaenoic acid (interactions with Gly117 and Glu197) and only one hydrogen bond interaction between the hydroxyl (-OH) at position 4- of the aliphatic chain and Gly117. All binding mode positions and descriptors of each abundant compounds obtained from *G. sphacelata* pulp and seeds extracts over the *h*BuChE are shown in **Figure S4**.



Figure S4. Predicted binding mode and predicted intermolecular interactions of all most abundant compounds in *G. sphacelata* pulp and seeds extracts and the residues of human butyrylcholinesterase (*h*BuChE) catalytic site. Yellow dotted lines indicate hydrogen bond interactions, cyan dotted lines represent π - π interactions and magenta dotted lines indicates T-Shaped interactions. **A.** Quercetin-3-*O*-glucoside-acetate (flavonoid) into the catalytic site; **B.** Lupinisoflavone (isoflavone) into the catalytic site; **C.** Genistein-7-*O*-diglucoside (isoflavone) into the catalytic site; **D.** Ononin (formononetin 7-*O*-glucoside) (isoflavone) into the catalytic site; **F.** Genistein-7-*O*-glucoside (isoflavone) into the catalytic site; **H.** Hydroxy-pentadecanoic acid (fatty acid) into the catalytic site; **H.** Hydroxy-pentadecanoic acid (fatty acid) into the catalytic site.

References

- 1. Adamo, C. and V. Barone, *Toward reliable density functional methods without adjustable parameters: The PBE0 model.* The Journal of chemical physics, 1999. **110**(13): p. 6158-6170.
- 2. Petersson, a., et al., *A complete basis set model chemistry*. *I. The total energies of closed-shell atoms and hydrides of the first-row elements.* The Journal of chemical physics, 1988. **89**(4): p. 2193-2218.
- 3. Frisch, A., Gaussian 09 User's Reference. 2009: Gaussian, Incorporated.
- 4. Greenblatt, H., et al., *Structure of acetylcholinesterase complexed with* (–)-*galanthamine at* 2.3 Å *resolution*. Febs Letters, 1999. **463**(3): p. 321-326.
- 5. Nachon, F., et al., *Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl-and butyryl-cholinesterase.* Biochemical Journal, 2013. **453**(3): p. 393-399.
- 6. Berman, H., et al., *RCSB Protein Data Bank: Structural biology views for basic and applied research*. Nucleic Acids Res, 2000. **28**: p. 235-242.
- 7. Silman, I., et al., *Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents*. 1994, Portland Press Limited.
- 8. Sussman, J.L., et al., Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science, 1991. 253(5022): p. 872-879.
- 9. Nicolet, Y., et al., *Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products.* Journal of Biological Chemistry, 2003. **278**(42): p. 41141-41147.
- 10. Tallini, L., et al., *Cholinesterase Inhibition Activity, Alkaloid Profiling and Molecular Docking of Chilean Rhodophiala (Amaryllidaceae)*. Molecules, 2018. **23**(7): p. 1532.
- 11. Thomsen, R. and M.H. Christensen, *MolDock: a new technique for high-accuracy molecular docking*. Journal of medicinal chemistry, 2006. **49**(11): p. 3315-3321.
- 12. DeLano, W.L., The PyMOL molecular graphics system. http://www. pymol. org, 2002.